What is Centogene's stock price target for 2024?

0 equities research analysts have issued twelve-month price targets for Centogene's shares. Their CNTG share price targets range from $1.50 to $1.50. On average, they predict the company's stock price to reach $1.50 in the next year. This suggests a possible upside of 211.9% from the stock's current price. View analysts price targets for CNTG or view top-rated stocks among Wall Street analysts .

How have CNTG shares performed in 2024?

Centogene's stock was trading at $1.20 at the beginning of the year. Since then, CNTG stock has decreased by 59.9% and is now trading at $0.4810. View the best growth stocks for 2024 here .

Are investors shorting Centogene?

Centogene saw a increase in short interest in March. As of March 31st, there was short interest totaling 11,900 shares, an increase of 5.3% from the March 15th total of 11,300 shares. Based on an average daily volume of 44,800 shares, the short-interest ratio is currently 0.3 days. Currently, 0.1% of the company's stock are sold short. View Centogene's Short Interest .

When is Centogene's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 21st 2024. View our CNTG earnings forecast .

How were Centogene's earnings last quarter?

Centogene (NASDAQ:CNTG) posted its quarterly earnings results on Wednesday, November, 24th. The company reported ($1.08) EPS for the quarter, missing analysts' consensus estimates of ($0.59) by $0.49. The company earned $35.60 million during the quarter, compared to analyst estimates of $31.91 million. During the same period in the previous year, the company earned ($0.32) EPS.

What guidance has Centogene issued on next quarter's earnings?

Centogene issued an update on its FY 2023 earnings guidance on Thursday, January, 18th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $52.2 million-$52.7 million, compared to the consensus revenue estimate of $57.6 million.

What other stocks do shareholders of Centogene own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Centogene investors own include Fulcrum Therapeutics (FULC) , Advanced Micro Devices (AMD) , OPKO Health (OPK) , Sorrento Therapeutics (SRNE) , VBI Vaccines (VBIV) , Aldeyra Therapeutics (ALDX) , Alimera Sciences (ALIM) , AngloGold Ashanti (AU) , Chimerix (CMRX) and Entasis Therapeutics (ETTX) .

When did Centogene IPO?

Centogene (CNTG) raised $60 million in an initial public offering (IPO) on Thursday, November 7th 2019. The company issued 4,000,000 shares at $14.00-$16.00 per share. SVB Leerink and Evercore ISI served as the underwriters for the IPO and Baird and BTIG were co-managers.

How do I buy shares of Centogene?

Shares of CNTG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:CNTG

Centogene (CNTG) Stock Price, News & Analysis

→ The #1 Investment of the Decade… (From Porter & Company) (Ad)

Free CNTG Stock Alerts

$0.48

-0.07 (-12.70%)

(As of 04/15/2024 ET)

Compare

Today's Range: $0.46
▼
$0.57
50-Day Range: $0.48
▼
$1.10
52-Week Range: $0.46
▼
$2.52

Volume: 86,629 shs
Average Volume: 44,864 shs
Market Capitalization: $13.03 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $1.50

Get Centogene alerts:

Centogene MarketRank™ Stock Analysis

Analyst Rating: 0.00 Rating Score
Upside/Downside: 211.9% Upside
$1.50 Price Target
Short Interest: Healthy
0.10% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.26
Upright™ Environmental Score
News Sentiment: 0.44
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.60) to ($0.97) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.72 out of 5 stars

Medical Sector

430th out of 929 stocks

Medical Laboratories Industry

11th out of 20 stocks

2.0

Analyst's Opinion

Amount of Analyst Coverage
Centogene has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.10% of the float of Centogene has been sold short.
Short Interest Ratio / Days to Cover
Centogene has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Centogene has recently increased by 5.31%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Centogene does not currently pay a dividend.
Dividend Growth
Centogene does not have a long track record of dividend growth.

4.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Centogene has received a 70.13% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Private genetic testing services", "Non-invasive prenatal testing services", and "Private medical screening services" products. See details.
Environmental Sustainability
The Environmental Impact score for Centogene is -1.26.

2.5

News and Social Media Coverage

News Sentiment
Centogene has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.65 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Centogene this week, compared to 1 article on an average week.
Search Interest
1 people have searched for CNTG on MarketBeat in the last 30 days.
MarketBeat Follows
Only 1 people have added Centogene to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Centogene insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 1.93% of the stock of Centogene is held by insiders.
Percentage Held by Institutions
Only 9.94% of the stock of Centogene is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Centogene are expected to grow in the coming year, from ($1.60) to ($0.97) per share.
Price to Book Value per Share Ratio
Centogene has a P/B Ratio of 1.66. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Porter & Company

The #1 Investment of the Decade…

Sam Altman, the CEO of OpenAI, has invested $375 million into a breakthrough technology, that legendary financial analyst Porter Stansberry believes… …could be the number-one investment of the decade.

To get all the details of this controversial tech – click here now.

About Centogene Stock (NASDAQ:CNTG)

Centogene N.V., together with its subsidiaries, engages in the research and development of products for human genetics in Europe, the Middle East, North America, Latin America, and the Asia Pacific. It provides data-driven answers to patients, physicians, and pharmaceutical companies for rare and neurodegenerative diseases. It operates through two segments: Pharmaceutical and Diagnostics. The company provides target and drug screening, clinical development, market access and expansion, as well as CENTOGENE Biodatabank licenses and insight report services. In addition, it offers various services, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors. Centogene N.V. was founded in 2006 and is headquartered in Rostock, Germany.

CNTG Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CNTG Stock News Headlines

April 4, 2024 | investing.com

Centogene faces Nasdaq delisting over share price

April 2, 2024 | globenewswire.com

CENTOGENE Receives Nasdaq Non-Compliance Notice

April 16, 2024 | Porter & Company (Ad)

The #1 Investment of the Decade…

March 22, 2024 | fool.com

Centogene (NASDAQ: CNTG)

March 19, 2024 | globenewswire.com

CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders

March 1, 2024 | finanznachrichten.de

Centogene NV: CENTOGENE Collaborates on Research Published in Science Showing Immunopathological Landscape of Human Pre-TCRa Deficiency

February 29, 2024 | it.investing.com

CENTOGENE scopre la carenza del recettore alfa delle cellule pre-T

February 29, 2024 | globenewswire.com

CENTOGENE Collaborates on Research Published in Science Showing Immunopathological Landscape of Human Pre-TCRα Deficiency

April 16, 2024 | Porter & Company (Ad)

The #1 Investment of the Decade…

February 28, 2024 | finanznachrichten.de

Centogene NV: CENTOGENE Explores Strategic Alternatives

February 28, 2024 | finanznachrichten.de

Centogene NV: CENTOGENE Announces Receipt of Nasdaq Notice of Delisting and Intention to Request a Hearing

February 28, 2024 | markets.businessinsider.com

Centogene Explores Strategic Alternatives, Incl. Sale

February 28, 2024 | markets.businessinsider.com

Centogene Announces Receipt Of Nasdaq Notice Of Delisting

February 28, 2024 | msn.com

Centogene to explores strategic alternatives, gets Nasdaq delisting notice; shares plunge

February 28, 2024 | globenewswire.com

CENTOGENE Explores Strategic Alternatives

February 28, 2024 | globenewswire.com

CENTOGENE Announces Receipt of Nasdaq Notice of Delisting and Intention to Request a Hearing

January 25, 2024 | finanznachrichten.de

Centogene NV: CENTOGENE and the Laboratory of Human Genetics of Infectious Diseases at Institut Imagine Announce Rare Disease Research Collaboration

January 25, 2024 | finance.yahoo.com

CENTOGENE and the Laboratory of Human Genetics of Infectious Diseases at Institut Imagine Announce Rare Disease Research Collaboration

January 24, 2024 | finanznachrichten.de

Centogene NV: CENTOGENE Receives French Research Tax Credit Accreditation

January 23, 2024 | finance.yahoo.com

CENTOGENE and The Michael J. Fox Foundation Announce Research Project to Validate Genetic Risk Factors of Parkinson’s Disease Using Multiomics

January 18, 2024 | finance.yahoo.com

CENTOGENE Announces Preliminary Full Year 2023 Revenue

December 21, 2023 | morningstar.com

Centogene NV Ordinary Shares CNTG

December 13, 2023 | finanznachrichten.de

Centogene NV: CENTOGENE's Frontotemporal Dementia (FTD) Genetic Study, EFRONT, Reaches Initial Patient Enrollment Milestone

December 13, 2023 | msn.com

Motus GI, C4 Therapeutics among healthcare movers

December 13, 2023 | msn.com

CCCC, XPOF and AUVI are among pre market gainers

December 13, 2023 | finance.yahoo.com

CENTOGENE’s Frontotemporal Dementia (FTD) Genetic Study, EFRONT, Reaches Initial Patient Enrollment Milestone

November 28, 2023 | finanznachrichten.de

Centogene NV: CENTOGENE and Lifera, a Public Investment Fund (PIF) Company, Complete Strategic Joint Venture Transaction

See More Headlines

Receive CNTG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Centogene and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/24/2021
Today: 4/15/2024
Next Earnings (Estimated): 5/21/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Medical laboratories
Sub-Industry: N/A
Current Symbol: NASDAQ:CNTG
CUSIP: N/A
CIK: 1757097
Web: www.centogene.com
Phone: 38180113500
Fax: N/A
Employees: 444
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $1.50
High Stock Price Target: $1.50
Low Stock Price Target: $1.50
Potential Upside/Downside: +179.6%
Consensus Rating
Rating Score (0-4): 0.00
Research Coverage: 0 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: $50.03 million
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.29 per share
Price / Book: 1.85

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: $15.04 million
Optionable: Not Optionable
Beta: -0.81

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Ms. Kim Stratton (Age 62)
CEO & Member of Management Board
Comp: $933.13k
Mr. Jose Miguel Coego Rios
CFO, Legal & IT and Member of Management Board
Dr. Peter Bauer M.D. (Age 54)
Chief Medical & Genomic Officer and Member of Management Board
Comp: $186.41k
Dr. Andrin Oswald M.D. (Age 52)
Ph.D., Advisor
Comp: $943.96k
Mr. Ian Rentsch
Chief Commercial Officer & GM of Pharma

Key Competitors

View All Competitors

CNTG Stock Analysis - Frequently Asked Questions

What is Centogene's stock price target for 2024?: 0 equities research analysts have issued twelve-month price targets for Centogene's shares. Their CNTG share price targets range from $1.50 to $1.50. On average, they predict the company's stock price to reach $1.50 in the next year. This suggests a possible upside of 211.9% from the stock's current price.
View analysts price targets for CNTG or view top-rated stocks among Wall Street analysts.
How have CNTG shares performed in 2024?: Centogene's stock was trading at $1.20 at the beginning of the year. Since then, CNTG stock has decreased by 59.9% and is now trading at $0.4810.
View the best growth stocks for 2024 here.
Are investors shorting Centogene?: Centogene saw a increase in short interest in March. As of March 31st, there was short interest totaling 11,900 shares, an increase of 5.3% from the March 15th total of 11,300 shares. Based on an average daily volume of 44,800 shares, the short-interest ratio is currently 0.3 days. Currently, 0.1% of the company's stock are sold short.
View Centogene's Short Interest.
When is Centogene's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 21st 2024.
View our CNTG earnings forecast.
How were Centogene's earnings last quarter?: Centogene (NASDAQ:CNTG) posted its quarterly earnings results on Wednesday, November, 24th. The company reported ($1.08) EPS for the quarter, missing analysts' consensus estimates of ($0.59) by $0.49. The company earned $35.60 million during the quarter, compared to analyst estimates of $31.91 million. During the same period in the previous year, the company earned ($0.32) EPS.

What guidance has Centogene issued on next quarter's earnings?: Centogene issued an update on its FY 2023 earnings guidance on Thursday, January, 18th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $52.2 million-$52.7 million, compared to the consensus revenue estimate of $57.6 million.
What other stocks do shareholders of Centogene own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Centogene investors own include Fulcrum Therapeutics (FULC), Advanced Micro Devices (AMD), OPKO Health (OPK), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Alimera Sciences (ALIM), AngloGold Ashanti (AU), Chimerix (CMRX) and Entasis Therapeutics (ETTX).
When did Centogene IPO?: Centogene (CNTG) raised $60 million in an initial public offering (IPO) on Thursday, November 7th 2019. The company issued 4,000,000 shares at $14.00-$16.00 per share. SVB Leerink and Evercore ISI served as the underwriters for the IPO and Baird and BTIG were co-managers.
How do I buy shares of Centogene?: Shares of CNTG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CNTG) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Centogene (CNTG) Stock Price, News & Analysis

Centogene MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Centogene Stock (NASDAQ:CNTG)

CNTG Stock Price History

CNTG Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

CNTG Stock Analysis - Frequently Asked Questions

Overall MarketRank^™